• 1. Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China; 2. Department of Blood Transfusion, Affiliated Hospital, Luzhou Medical College, Luzhou 646000, China;3. Department of Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China;4. Department of Nephrology, the Second of Affiliated Hospital, Luzhou Medical College, Luzhou 646000, China;
HUANG Songmin, Email: hsongm@medmail.com.cn
Export PDF Favorites Scan Get Citation

Objective  To evaluate the efficacy and safety of tripterygium for diabetic nephropathy.
Methods  All randomized or quasi-randomized controlled trials (RCTs or quasi-RCTs) of tripterygium for biabetic nephropathy were collected from The Cochrane Library (Issue 1, 2010), MEDLINE (1996 to March 2010), CNKI (1994 to March 2010), and CBM (1978 to March 2010). Two reviewers evaluated the quality of the trials and extracted the data independently. RevMan 5.0 software was used for meta-analyses.
Results  A total of 12 RCTs involving 862 patients were identified. The methodology of the included trials was poor and potential publication bias existed. The meta-analyses results showed: (1) Compared with the conventional treatment, the tripterygium showed more effects in reducing the 24-hour urinary protein (Clinical phase: WMD= –0.49, 95%CI –0.63 to –0.34, No phase: WMD= –0.60, 95%CI –0.96 to –0.24), and the urinary albumin excretion rate (UAER) (WMD= –148.75, 95%CI –238.01 to –59.48) was higher than that of the conventional treatment. (2) There were no significant differences between the two groups in the effect on the serum creatinine (Clinical phase: WMD= –8.43, 95%CI –18.15 to 1.29, No phase: WMD= –0.66, 95%CI –2.12 to 0.79) and creatinine clearance rate (WMD= 1.74, 95%CI –6.34 to 9.83). (3) Without enough data, it was uncertain to define the effect of tripterygium on lipids, blood pressure of the DN patients. (4) No severe adverse events or allergic reactions were reported.
Conclusion  Tripterygium may be a kind of medicine relatively safe and effective for diabetic nephropathy. However, the evidence is not b enough because of some low-quality trials and publication bias. Rigorously-designed, randomized, double-blind, and placebo-controlled trials of tripterygium for diabetic nephropathy are needed to further assess the effect.

Citation: WU Weihua,WANG Han,ZHANG Maoping,HUANG Songmin. Effects of Tripterygium on Diabetic Nephropathy: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2010, 10(6): 693-699. doi: 10.7507/1672-2531.20100478 Copy

  • Previous Article

    Meta-analysis of Anti-Vascular Endothelial Growth Factor Agents Therapy for Advanced Renal Cell Carcinoma
  • Next Article

    Shenmai Injection for Children with Viral Myocarditis: A Systematic Review